Incyte (INCY) Revenue and Net Income History
Historical revenue, operating income and net income for Incyte (INCY) over the last 10 years. The current revenue for Incyte as of June 21, 2018 is $1.54B.
|Medical||Medical - Biomedical and Genetics||$15.565B||$1.536B|
|Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. They have a diverse and growing portfolio of product candidates, including both small and large molecules.|